| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2024-104 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于万孚转债回售结果的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本次"万孚转债"回售不会对公司财务状况、股本结构、经营成果及现金流 量产生重大影响，不会损害公司的债务履行能力和持续经营能力。 三、本次可转换公司债券回售的后续事项 1、债券代码：123064，债券简称：万孚转债 2、回售价格：100.266 元人民币/张（含息、税） 一、本次可转换公司债券回售的公告情况 广州万孚生物技术股份有限公司（以下简称"公司"）根据《深圳证券交易 所创业板股票上市规则》、《深圳证券交易所上市公司自律监管指引第 15 号—— 可转换公司债券》等法律法规的有关规定以及《广州万孚生物技术股份有限公司 向不特定对象发行可转换公司债券募集说明书》的约定，于 2024 年 10 月 22 日、 2024 年 10 月 23 日、2024 年 10 月 24 ...

Investment Rating - Buy/Maintain rating for Wondfo Biotech (300482) [2] Core Views - Wondfo Biotech's international business is rapidly expanding, while its domestic business shows strong resilience [2] - The company's global layout is accelerating, with COVID-19 single test and fentanyl test reagents obtaining FDA registration certificates [4] - Domestic business demonstrates strong resilience, with 900-speed chemiluminescence installations exceeding expectations [5] - Financial expense ratio is slightly affected by exchange gains and losses, but profitability has improved year-on-year [6] Financial Performance - In the first three quarters of 2024, Wondfo Biotech achieved revenue of 2,181 million yuan, a year-on-year increase of 8.83% [3] - Net profit attributable to the parent company was 436 million yuan, a year-on-year increase of 9.04% [3] - In the third quarter of 2024, revenue was 606 million yuan, a year-on-year increase of 17.51% [3] - Net profit attributable to the parent company in Q3 2024 was 80 million yuan, a year-on-year increase of 22.70% [3] International Business - International business maintains relative stability, with quantitative business achieving rapid growth [4] - Single-person luminescence products in overseas markets have seen significant year-on-year growth [4] - Quantitative platform revenue and proportion have significantly increased, driven by comprehensive instrument deployment [4] - Fentanyl urine test reagent POC professional version and home self-test OTC products have obtained FDA 510(k) approval [4] - Self-developed COVID-19 home test (OTC) product has passed FDA 510(k) approval [4] Domestic Business - Domestic quantitative business saw slight year-on-year growth in Q3 2024, with chemiluminescence business growing rapidly [5] - 900-speed chemiluminescence high-speed machine installations exceeded expectations in the first three quarters of 2024 [5] - 200-speed instrument installations met the 2024 target [5] - Colloidal gold platform achieved rapid year-on-year growth in Q3 2024, exceeding the business rhythm set at the beginning of the year [5] Profitability and Expenses - Comprehensive gross profit margin increased by 0.59pct to 63.43% in the first three quarters of 2024 [6] - Sales expense ratio, management expense ratio, and R&D expense ratio decreased by 1.61pct, 0.50pct, and 0.52pct respectively [6] - Financial expense ratio increased by 1.22pct due to exchange rate fluctuations [6] - Overall net profit margin increased by 0.32pct to 20.16% [6] - In Q3 2024, comprehensive gross profit margin increased by 0.30pct to 61.07% [6] - Net profit margin in Q3 2024 increased by 0.87pct to 13.45% [6] Future Projections - Expected revenue for 2024-2026 is 3,101 million yuan, 3,796 million yuan, and 4,620 million yuan, with year-on-year growth rates of 12%, 22%, and 22% respectively [8] - Expected net profit attributable to the parent company for 2024-2026 is 638 million yuan, 782 million yuan, and 982 million yuan, with year-on-year growth rates of 31%, 23%, and 26% respectively [8] - EPS for 2024-2026 is expected to be 1.32, 1.62, and 2.04 respectively [8] - PE ratio for 2024 is 19 times based on the closing price on October 29, 2024 [8]

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2024-103 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于万孚转债恢复转股的提示性公告 3、暂停转股时间：2024 年 10 月 25 日至 2024 年 10 月 31 日 4、恢复转股时间：2024 年 11 月 1 日 广州万孚生物技术股份有限公司（以下简称"公司"）的股票自 2024 年 9 月 1 日至 2024 年 9 月 10 日连续七个交易日的收盘价格低于当期转股价 48.56 元/股的 70%，即 33.99 元/股；2024 年 9 月 11 日至 2024 年 10 月 22 日连续二 十三个交易日的收盘价格低于当期转股价 48.58 元/股（因部分限制性股票回购 注销导致公司股本减少，自 2024 年 9 月 11 日起，"万孚转债"转股价格由 48.56 元/股调整为 48.58 元/股）的 70%，即 34.01 元/股。"万孚转债"处于 最后两个计息年度。根据《广州万孚生物技术股份有限公司向不特定对象发行 可转换公司债 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： | 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2024-102 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于万孚转债回售的第六次提示性公告 1、回售价格：100.266 元人民币/张（含息、税） 2、回售条件触发日：2024 年 10 月 22 日 3、回售申报期：2024 年 10 月 25 日至 2024 年 10 月 31 日 4、发行人资金到账日：2024 年 11 月 5 日 5、回售款划拨日：2024 年 11 月 6 日 6、投资者回售款到账日：2024 年 11 月 7 日 7、回售期申报期内万孚转债暂停转股 8、本次回售不具有强制性 9、在回售款划拨日之前，如已申报回售的可转换公司债券发生司法冻结或 扣划等情形，债券持有人本次回售申报业务失效。 2、回售价格 根据《募集说明书》的约定，当期应计利息的计算公式为：IA=B×i×t/365 IA：指当期应计利息； B：指本次发 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 2.765 billion yuan in 2023, with a year-on-year growth rate of -51%. The forecast for 2024 is 3.127 billion yuan, representing a 13% growth [1] - The net profit attributable to the parent company for 2023 is projected to be 488 million yuan, with a significant year-on-year decline of -59%. The expected net profit for 2024 is 632 million yuan, indicating a recovery with a growth rate of 30% [1] - The company has shown a strong recovery in its conventional business, with significant growth in international operations and a steady improvement in profitability [1][2] Financial Performance Summary - **Revenue (in million yuan)**: - 2022: 5,681 - 2023: 2,765 - 2024E: 3,127 - 2025E: 3,873 - 2026E: 4,810 [1] - **Net Profit (in million yuan)**: - 2022: 1,197 - 2023: 488 - 2024E: 632 - 2025E: 780 - 2026E: 968 [1] - **Earnings Per Share (in yuan)**: - 2022: 2.49 - 2023: 1.01 - 2024E: 1.31 - 2025E: 1.62 - 2026E: 2.01 [1] - **Return on Equity (ROE)**: - 2022: 26% - 2023: 11% - 2024E: 12% - 2025E: 13% - 2026E: 14% [1] Market and Business Outlook - The company has seen a significant recovery in its conventional business, with a notable increase in revenue and net profit in the third quarter of 2024, driven by the recovery of routine business and stable expense management [1] - The international business is expanding rapidly, with ongoing localization efforts and strong growth in the international division, supported by WHO certification for products [1][2] - The company is expected to maintain high growth potential, with a focus on product-driven growth and a stable outlook for its U.S. operations [1][2]

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2024-101 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于万孚转债回售的第五次提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、回售价格：100.266 元人民币/张（含息、税） 2、回售条件触发日：2024 年 10 月 22 日 3、回售申报期：2024 年 10 月 25 日至 2024 年 10 月 31 日 4、发行人资金到账日：2024 年 11 月 5 日 5、回售款划拨日：2024 年 11 月 6 日 6、投资者回售款到账日：2024 年 11 月 7 日 7、回售申报期内万孚转债暂停转股 8、本次回售不具有强制性 9、在回售款划拨日之前，如已申报回售的可转换公司债券发生司法冻结或 扣划等情形，债券持有人本次回售申报业务失效。 广州万孚生物技术股份有限公司（以下简称"公司"）的股票自 2024 年 9 月 1 日至 2024 年 9 月 10 日连续七个交 ...

Financial Performance - In Q3 2024, the company achieved operating revenue of 606.11 million yuan, a year-on-year increase of 17.51% [1] - Net profit attributable to shareholders reached 80.14 million yuan, up 22.70% from the previous year [1] - Net profit excluding non-recurring gains and losses was 62.70 million yuan, reflecting a significant growth of 49.89% year-on-year [1] Business Segments - The international department maintained stable qualitative business while experiencing rapid growth in quantitative business, particularly in overseas fluorescence platforms [1] - The U.S. subsidiary's toxicology business remained stable, with significant growth expected in respiratory infectious disease testing, including new COVID-19 and flu combination tests [2] - Domestic operations are divided into qualitative and quantitative segments, with qualitative business showing rapid growth in infectious disease testing [2] Market Expansion - The company is actively expanding sales channels, focusing on offline pharmacies, supermarkets, and online platforms like Amazon [2] - Localized factories are being established in various countries to mitigate potential policy risks and enhance market opportunities [3] - The company has successfully registered respiratory combination tests in several countries, anticipating future business opportunities [4] Cost and Profitability - Sales and management expenses increased in Q3 due to the recognition of stock incentive costs, but overall expense ratios have decreased compared to the previous year [3] - Gross margin showed a slight improvement due to product structure optimization and increased sales of higher-margin products [4] Future Outlook - The international department is expected to continue strong performance, with significant growth anticipated in the fourth quarter driven by respiratory disease products [4] - The company remains confident in achieving its annual revenue and profit targets despite external challenges [4]

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2024-100 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于万孚转债回售的第四次提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 5、回售款划拨日：2024 年 11 月 6 日 6、投资者回售款到账日：2024 年 11 月 7 日 7、回售申报期内万孚转债暂停转股 8、本次回售不具有强制性 9、在回售款划拨日之前，如已申报回售的可转换公司债券发生司法冻结或 扣划等情形，债券持有人本次回售申报业务失效。 广州万孚生物技术股份有限公司（以下简称"公司"）的股票自 2024 年 9 月 1 日至 2024 年 9 月 10 日连续七个交易日的收盘价格低于当期转股价 48.56 元/股 的 70%，即 33.99 元/股；2024 年 9 月 11 日至 2024 年 10 月 22 日连续二十三个 交易日的收盘价格低于当期转股价 48.58 元/股（因部分限制性股票回购注销导致 公 ...

Investment Rating - The report maintains a "Recommended" rating for the company [2][4]. Core Views - The company's performance in Q3 2024 met expectations, with a revenue of 2.181 billion yuan (+8.83%) and a net profit of 436 million yuan (+9.04%) for the first nine months of 2024. The Q3 revenue was 606 million yuan (+17.51%) and net profit was 80 million yuan (+22.70%) [2]. - The company demonstrated resilience in a challenging domestic market, with growth driven by a gradual recovery in hospital admissions and successful overseas product registrations [2][4]. - The gross margin for Q3 2024 was 61.07%, slightly up by 0.3 percentage points year-on-year, benefiting from an optimized product mix. The company also achieved a significant reduction in operating expense ratios, indicating improved operational efficiency [2][4]. - Recent advancements in overseas product certifications are expected to support rapid growth in international business, including malaria detection products and FDA approvals for fentanyl and COVID-19 testing kits [2][4]. Financial Forecasts - The company is projected to achieve revenues of 3.0905 billion yuan in 2024, with a growth rate of 11.78%. Net profit is expected to reach 655.46 million yuan, reflecting a growth rate of 34.42% [5]. - For the years 2025 and 2026, revenues are forecasted at 3.71212 billion yuan and 4.40689 billion yuan, with respective growth rates of 20.11% and 18.72%. Net profits are expected to be 811.60 million yuan and 982.11 million yuan, with growth rates of 23.82% and 21.01% [5][9].

| 证券代码：300482 | 证券简称：万孚生物 公告编号：2024-099 | | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | 广州万孚生物技术股份有限公司 关于万孚转债回售的第三次提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、回售价格：100.266 元人民币/张（含息、税） 2、回售条件触发日：2024 年 10 月 22 日 3、回售申报期：2024 年 10 月 25 日至 2024 年 10 月 31 日 4、发行人资金到账日：2024 年 11 月 5 日 5、回售款划拨日：2024 年 11 月 6 日 6、投资者回售款到账日：2024 年 11 月 7 日 7、回售申报期内万孚转债暂停转股 8、本次回售不具有强制性 9、在回售款划拨日之前，如已申报回售的可转换公司债券发生司法冻结或 扣划等情形，债券持有人本次回售申报业务失效。 广州万孚生物技术股份有限公司（以下简称"公司"）的股票自 2024 年 9 月 1 日至 2024 年 9 月 10 日连续七个交易日的收盘价格低于当 ...